Aims: To evaluate the tolerability, acceptability, and potential efficacy of the selective norepinephrine transporter inhibitor atomoxetine for treating amphetamine-type stimulant (ATS) use disorder in patients receiving buprenorphine/naloxone (BUP/NX). (Source: Drug and Alcohol Dependence)
Pilot study of atomoxetine for BUP/NX-maintained patients with co-occurring opioid and ATS use disorder
Call 1 (888) 460-6556 to speak with a counselor.
Pilot study of atomoxetine for BUP/NX-maintained patients with co-occurring opioid and ATS use disorder
Call 1 (888) 460-6556 to speak with a counselor.
Aims: To evaluate the tolerability, acceptability, and potential efficacy of the selective norepinephrine transporter inhibitor atomoxetine for treating amphetamine-type stimulant (ATS) use disorder in patients receiving buprenorphine/naloxone (BUP/NX). (Source: Drug and Alcohol Dependence)
